12:00 AM
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Linifanib: Phase II data

In an open-label Phase II trial in 53 patients who previously failed treatment with Sutent sunitinib, 0.25 mg/kg daily oral linifanib led to an ORR of 9.4%, with median PFS and OS of 5.4 and 13.3 months, respectively. The...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >